The results demonstrated that the expression of HSPA4 positively correlated with PD-1 and CTLA-4 in HCC, indicating that targeting HSPA4 might increase the efficacy of immune checkpoint inhibitors in HCC. The gene discussed is HSPA4; the disease is hepatocellular carcinoma.